Scientists track MS drug in breastmilk to ensure infant safety
NCT ID NCT04998851
Summary
This study aimed to understand if a multiple sclerosis (MS) medication called ocrelizumab passes into breastmilk and affects breastfeeding infants. Researchers measured the drug levels in breastmilk and checked the babies' immune cells and responses to standard childhood vaccines. The goal was to gather safety information for mothers with MS who wish to breastfeed while receiving this treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE SCLEROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Brigham and Womens Hospital
Boston, Massachusetts, 02115, United States
-
Hosp. Clinico San Carlos
Madrid, 28040, Spain
-
Hospital of the University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States
-
Memorial Healthcare Institute for Neurosciences and Multiple Sclerosis
Owosso, Michigan, 48867, United States
-
Northwestern Memorial Hospital
Chicago, Illinois, 60611-2987, United States
-
Queen Mary University of London
London, EC1M 6BQ, United Kingdom
-
University Of Colorado
Aurora, Colorado, 80045, United States
-
University of California San Francisco
San Francisco, California, 94158, United States
Conditions
Explore the condition pages connected to this study.